Lenograstim (rhG-CSF)

Lenograstim (rhG-CSF) In Dogs & Cats: Uses, Dosage and Side Effects

Overview

• Recombinant human granulocyte-colony stimulating factor (rhG-CSF).
• Activates proliferation and differentiation of granulocyte progenitor cells and enhances granulopoiesis.

Uses of Lenograstim (rhG-CSF)

• Management of febrile patients with neutrophil counts <1 x109/l.
• There are few reports on the use of G-CSF in dogs and cats; filgastrim is more commonly used.

Dose of Lenograstim (rhG-CSF) in Dogs and Cats

Dogs:

• 19.2 million IU/m2 i.v. (over 30 min), s.c. q24h for 3–5 days.

Cats:

• No information is available.

Side Effects of Lenograstim (rhG-CSF) in Dogs and Cats

• A variety of adverse effects have been reported in humans, including musculoskeletal pain, transient hypotension, dysuria, allergic reactions, proteinuria, haematuria and increased liver enzymes.
• Reported adverse effects are bone pain at high doses and irritation at the injection site.

Contraindications of Lenograstim (rhG-CSF) in Dogs and Cats

• No information is available.

Some Notes:

• In humans, steroids and lithium may potentiate the release of neutrophils during G-CSF therapy.
• Concurrent administration with chemotherapy may increase the incidence of adverse
  effects.
• G-CSF should be given at least 24 hours after the last dose of chemotherapy as the stimulatory effects of G-CSF on haemopoietic precursors render them more susceptible to the effects of chemotherapy.